From TAVI to mitral and tricuspid - Applying evidence to expand patients' treatment options

Expanding treatment options to modify the course of atrioventricular valvular heart disease - Sponsored by Edwards Lifesciences

Anchorperson: B. Prendergast

Discussants: P. Lurz, F. Praz

Summary

Nowadays, there is an increasing range of treatment options as far as tricuspid and mitral regurgitations are concerned. Bernard Prendergast, Philipp Lurz, Fabien Praz and Maurizio Taramasso discuss the challenges and needs regarding mitral and tricuspid valve disease treatment. They also consider what is needed to develop an understanding of TR patient outcomes with various transcatheter options, as well as the updated knowledge on the latest clinical data and MR patient outcomes with the PASCAL platform.

Learning Objectives

To understand the challenges and needs regarding mitral and tricuspid valve disease treatment
To develop an understanding of TR patient outcomes with the various transcatheter options Edwards Lifesciences offers
To update knowledge on the latest clinical data and discuss MR patient outcomes with the PASCAL platform